Drug class in one race
ALK / ROS1 drugs for Non-Small Cell Lung Cancer
5 tracked ALK / ROS1 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the ALK / ROS1 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 approved / phase 44 Phase 3
Head-to-head evidence: Foritinib succinate vs Lorlatinib · Foritinib succinate vs XZP-3621 · Lorlatinib vs XZP-3621 · TGRX-326 vs WX-0593